MedTrace Logo

Preventive Approach Using Venlafaxine

NCT05875610 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-05-25

No results posted yet for this study

Summary

Peripheral and Motor neuropathy represent a main obstacle for a better quality of life for cancer patients, Venlafaxine is introduced in a new dosing regimen for treating of oxaliplatin and taxanes induced peripheral neuropathy in cancer patients.

Conditions

  • Peripheral Neuropathy Due to Chemotherapy

Interventions

DRUG

Venlafaxine 75 MG

Venlafaxine 75 mg extended release capsules for a 7-days duration

DRUG

Gabapentin 400 mg

Gabapentin 400 mg capsules

Sponsors & Collaborators

  • Mit Ghamr Oncology Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
24 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2023-10-01
Completion
2023-12-01
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05875610 on ClinicalTrials.gov